Tianjin Tianyao Pharmaceuticals Co., Ltd.

Shanghai Stock Exchange 600488.SS

Tianjin Tianyao Pharmaceuticals Co., Ltd. Revenue Per Share for the year ending December 31, 2023: USD 0.49

Tianjin Tianyao Pharmaceuticals Co., Ltd. Revenue Per Share is USD 0.49 for the year ending December 31, 2023, a -0.33% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Tianjin Tianyao Pharmaceuticals Co., Ltd. Revenue Per Share for the year ending December 31, 2022 was USD 0.49, a -9.39% change year over year.
Tianjin Tianyao Pharmaceuticals Co., Ltd. Revenue Per Share for the year ending December 31, 2021 was USD 0.54, a 23.55% change year over year.
Tianjin Tianyao Pharmaceuticals Co., Ltd. Revenue Per Share for the year ending December 31, 2020 was USD 0.44, a 14.05% change year over year.
Tianjin Tianyao Pharmaceuticals Co., Ltd. Revenue Per Share for the year ending December 31, 2019 was USD 0.38, a 18.61% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Shanghai Stock Exchange: 600488.SS

Tianjin Tianyao Pharmaceuticals Co., Ltd.

CEO	Mr. Shuxiang Li
IPO Date	June 18, 2001
Location	China
Headquarters	No. 19, Xinye 9th Street
Employees	2,678
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Chemicals & Advanced Materials Drugstores & Retail Pharmacies Personal Care Petrochemicals Plastics

Description

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, manufacture, and export of pharmaceutical APIs in Asia. It primarily provides corticosteroid, cardio cerebrovascular, and analgesic APIs and formulations. The company offers bulk drugs, including dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinlone acetonide acetate, prednisone acetate, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone acetonide, clobetasol propionate, betamethasone, methylprednisolone hydrocortisone acetate, methylprednisolone, and triamcinolone. The company is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE : 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.

Key trends

Past 5 years